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and emesis. In the present study, we investigated the anti-
obesity effects and antioxidant activity of KE-06.
Methods: 3T3-L1 preadipocytes were differentiated into
adipocytes with or without KE-06. After differentiation, we
measured Oil Red O staining, glycerol-3-phosphate dehy-
drogenase (GPDH) activity and leptin production in 3T3-L1
adipocytes. In addition, we analyzed its effect on scavenging
activities of 2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic
acid) (A BTS) and 2,2’-diphenyl-1-picrylhydrazyl (DPPH) radi-
cals in in vitro systems. Its effect on low-density lipoprotein
(LD L) oxidation was assessed by measuring production of
malondialdehyde (MDA).
Results: KE-06 signiﬁcantly inhibited lipid accumulation
and triglyceride production, and mediated GPDH, a major
enzyme in the process of adipogenesis. Consistent with this,
KE-06 stimulation signiﬁcantly decreased the amount of lep-
tin in 3T3-L1 adipose cells. Furthermore, KE-06 enhanced the
scavenging activities on ABTS and DPPH radicals. The gener-
ation of MDA during LDL oxidation was signiﬁcantly reduced
by KE-06 treatment.
Conclusion:Overall, our ﬁndings suggest thatKE-06has the
potential for anti-adipogenic activity and antioxidant proper-
ties.
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Purpose: Liver ﬁbrosis is the key pathological changewhich
is arisen by most of chronic hepatic injuries. The progress of
hepatic ﬁbrosis determines the clinical outcome of patients,
but no therapeutics for the disease exists yet. The objective of
the present study is to present the overall status for CGXdevel-
opment regarding its clinical backgrounds, pharmacological
studies in animal models, and current process of randomized
clinical trial.
Methods: CGX has been used for patients suffering various
liver diseases, including chronic viral hepatitis and alcoholic
liver disorders. The safety study for CGX using rats and bea-
gle dogs, and pharmacological actions in animal models using
chemicals (CCl4, DMN, or TAA), chronic alcohol consump-
tion, choline-deﬁcient (MCD) diet, and bile duct ligation (BDL)
were presented respectively. The objective of the present
study is to present the overall status for CGX development
regarding its clinical backgrounds, pharmacological studies in
animal models, and current process of randomized clinical
trial.
Results: CGX is a modiﬁcation of a traditional Korean
herbal medicine, which is under clinical trial phase III for
hepatoﬁbrosis therapeutic effect. The main mechanisms
of CGX related to anti-hepatoﬁbrotic effects involve the
inhibition of hepatic stellate cells producing extracellular
matrix (ECM), down-regulation of pro-ﬁbrogenic cytokines
(TGF-, PDGF, CTGF), and modulation of oxidative stressors
and enhancements of antioxidant components. In addition,
microarray experiment revealed the regulative action of CGX
on VEGF gene expression.
Conclusion: Various amimal data strongly expected that
multi-sites clinical trial evidences the ﬁbro-therapeutic
effects in patients with chronic viral or alcoholic liver
diseases.
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Purpose: Gleditsia sinensis thorns have been used in
Korean medicine to treat diverse diseases including throm-
bosis and relieve symptoms similar to cancer. The present
study aims to (1) determine the anti-angiogenic effects of the
ethanol extract of Gleditsia sinensis thorns (EEGS) in vitro and
invivo, (2) evaluate anti-tumorpotential in vivo, (3) identify the
active constituent of EEGS, and (4) understand its underlining
mechanism.
Methods: EEGS was prepared by maceration of dried
powder of Gleditsia sinensis thorns in 80% EtOH. Anti-
angiogenic effects of EEGS were determined in vitro by
quantifying HUVEC-mediated cell migration and tube for-
mation, and in vivo by measuring new blood vessel
formation into the pro-angiogenic factors-imbeddedmatrigel.
Anti-tumor potential of EEGS was evaluated using a tumor-
xenografted mouse model. Isolation and identiﬁcation of
active constituent from EEGS were carried out by activity-
guided fractionation and NMR-Mass spectroscopy, respec-
tively. Alteration of gene expression following drug treat-
ment was determined by conventional molecular biological
methods.
Results: EEGS inhibited proliferation of HUVEC without
affecting cell viability. Angiogenic properties of HUVEC, such
as cell migration and tube formation, were signiﬁcantly
inhibited by EEGS. Formation of new blood vessels induced
by pro- angiogenic factors and growth of xenografted tumors
were suppressed by EEGS as determined by in vivo ani-
malmodels. HPLC-NMR-Mass spectroscopic analyses revealed
that cytochalasin H is an active anti-angiogenic constituent
of EEGS. Anti-angiogenic potential of EEGS and cytochalasin
H was related with the reduced expression of pro-angiogenic
factors, such as EDN1 and MMP2.
Conclusion: Taken together, our ﬁndings suggest that EEGS
can inhibit angiogenesis as well as tumor growth by down-
regulating expression of pro-angiogenic factors. Therefore,
EEGS can be considered as a good starting material to develop
a novel anti-cancer drug targeting angiogenesis. This study
